会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 6. 发明授权
    • Benzenesulphonamide compounds
    • 苯磺酰胺化合物
    • US06541471B1
    • 2003-04-01
    • US10195018
    • 2002-07-12
    • Gilbert LavielleThierry DubuffetBernard CimetiereTony VerbeurenSerge SimonetChristine Vayssettes-Courchay
    • Gilbert LavielleThierry DubuffetBernard CimetiereTony VerbeurenSerge SimonetChristine Vayssettes-Courchay
    • A61K315375
    • C07D275/06C07C311/19C07D295/088C07D413/04C07D417/04
    • A compound of formula (I): wherein: G represents a group such as: wherein R1 and R2 independently represent a hydrogen atom or an alkyl, cycloalkyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl or heteroarylalkyl group, or, R1 and R2 together with the nitrogen atom form a heterocycloalkyl group, R3 represents a hydrogen atom or an alkyl or optionally substituted phenyl group, Ra represents a hydroxy group, a linear or branched (C1-C6)alkoxy group or an amino group, Rb and Rc, which may be identical or different, each represents a hydrogen atom, a halogen atom, an alkyl group, an alkoxy group, a hydroxy group or a trihaloalkyl group, m is an integer of from 0 to 1 inclusive, n and q are integers of from 0 to 6 inclusive, p and r are integers of from 1 to 6 inclusive, its enantiomers and diastereoisomers, and addition salts thereof with a pharmaceutically acceptable acid or base; and medicinal products containing the same which are useful as a TXA2 receptor antagonist and a 5-HT2 receptor antagonist.
    • 式(I)的化合物:其中:G表示如下基团:其中R1和R2独立地表示氢原子或烷基,环烷基,芳基,芳基烷基,环烷基,环烷基烷基,杂芳基或杂芳基烷基,或R1和R2 与氮原子一起形成杂环烷基,R 3表示氢原子或烷基或任选取代的苯基,R a表示羟基,直链或支链(C 1 -C 6)烷氧基或氨基,R b和R c, 可以相同或不同,分别表示氢原子,卤素原子,烷基,烷氧基,羟基或三卤代烷基,m为0〜1的整数,n和q为 0〜6,p和r为1〜6的整数,其对映异构体和非对映异构体及其与药学上可接受的酸或碱的加成盐; 和含有它们的药物,其可用作TXA2受体拮抗剂和5-HT2受体拮抗剂。
    • 9. 发明授权
    • Benzenesulfonylamine compounds, process for preparing them and
pharmaceutical compositions
    • 苯磺酰胺化合物,其制备方法和药物组合物
    • US6013667A
    • 2000-01-11
    • US32587
    • 1998-02-27
    • Gilbert LavielleBernard CimetiereTony VerbeurenSerge SimonetJean-Jacques Descombes
    • Gilbert LavielleBernard CimetiereTony VerbeurenSerge SimonetJean-Jacques Descombes
    • A61K31/18A61K31/195A61K31/215A61P7/02A61P9/08A61P9/10C07C303/40C07C311/16C07C311/19C07C311/21C07C381/00A61K31/21
    • C07C311/19C07C311/21C07C381/00C07C2102/10
    • Compounds of formula (I): in which:R.sub.a and R.sub.b, identical or different, represent hydrogen or alkyl or together form a bond,R.sub.C represents hydroxyl optionally substituted alkoxy, or optionally substituted amino,R.sub.1 represents hydrogen or --O--NO.sub.2, --O--NO, or --S--NO,R.sub.2 and R.sub.3, identical or different, represent hydrogen, alkyl, or optionally substituted phenyl,X represents oxygen or --NH--CO--,m represents 0 or 1,n represents an integer such that 0.ltoreq.n.ltoreq.6,p represents 0 or 1,R.sub.4 represents hydrogen, optionally substituted alkyl, optionally substituted phenyl, or a group as defined in the description,R.sub.5 represents hydrogen or alkyl,R.sub.6 represents hydrogen or alkyl,or R.sub.5 and R.sub.6 together form a chain --(CH.sub.2).sub.t -- in which t represents 1 or 2,q represents 0, 1, or 2,r represents an integer such that 0.ltoreq.r.ltoreq.6,R.sub.d and R.sub.e, identical or different, represent hydrogen, halogen, alkyl, alkoxy, hydroxyl, or trihaloalkyl, it being understood that at least one --O--NO.sub.2, O--NO, or S--NO groupis present in R.sub.1, R.sub.4 or R.sub.c ; process of preparing same, pharmaceutical compositions thereof, and their use as TXA.sub.2 -receptor antagonists and NO donors.
    • 式(I)化合物:其中:R a和R b相同或不同,代表氢或烷基或一起形成键,RC表示羟基任选取代的烷氧基或任选取代的氨基,R 1表示氢或-O-NO 2, O-NO或-S-NO,R 2和R 3相同或不同,表示氢,烷基或任选取代的苯基,X表示氧或-NH-CO-,m表示0或1,n表示整数,使得 0表示0或1,R4表示氢,任选取代的烷基,任选取代的苯基或说明书中定义的基团,R 5表示氢或烷基,R 6表示氢或烷基,或 R5和R6一起形成链 - (CH 2)t-,其中t表示1或2,q表示0,1或2,r表示0以及r和r的整数, 相同或不同,代表氢,卤素,烷基,烷氧基,羟基或三卤代烷基,应理解至少有一个-O-NO 2,O-NO或S-NO基团存在于 R1,R4或Rc; 其制备方法,其药物组合物及其作为TXA2受体拮抗剂和NO供体的用途。